For the quarter ending 2026-03-31, ATNM has $45,438K in assets. $43,134K in debts. $42,132K in cash and cash equivalents.
| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Cash and cash equivalents | 42,132 | 47,998 | 53,391 | 59,928 |
| Prepaid expenses and other current assets | 1,129 | 1,383 | 975 | 1,101 |
| Total current assets | 43,261 | 49,381 | 54,366 | 61,029 |
| Property and equipment, net of accumulated depreciation of 1,094 and 1,064 | 268 | 295 | 226 | 271 |
| Restricted cash long term | 337 | 335 | 332 | 329 |
| Operating leases right-of-use assets, net | 1,565 | 1,754 | 1,215 | 1,373 |
| Finance leases right-of-use assets, net | 7 | 10 | 12 | 15 |
| Total assets | 45,438 | 51,775 | 56,151 | 63,017 |
| Accounts payable and accrued expenses | 6,615 | 7,247 | 6,224 | 7,714 |
| Operating leases current liability | 726 | 711 | 599 | 589 |
| Finance leases current liability | 8 | 11 | 11 | 11 |
| Long-term finance lease obligations | - | - | 2 | 5 |
| Total current liabilities | 7,349 | 7,969 | 6,834 | 8,314 |
| Long-term license revenue deferred | 35,000 | 35,000 | 35,000 | 35,000 |
| Long-term operating lease obligations | 785 | 972 | 531 | 685 |
| Total liabilities | 43,134 | 43,941 | 42,367 | 44,004 |
| Common stock, 0.001 par value 1,000,000,000 shares authorized 31,374,991 and 31,195,891 shares issued and outstanding, at march 31, 2026 and december 31, 2025, respectively | 31 | 31 | 31 | 31 |
| Additional paid-in capital | 417,547 | 417,536 | 417,526 | 417,624 |
| Accumulated other comprehensive loss | -39 | -20 | - | - |
| Accumulated deficit | -415,235 | -409,713 | -403,773 | -398,642 |
| Total stockholders equity | 2,304 | 7,834 | 13,784 | 19,013 |
| Total liabilities and stockholders equity | 45,438 | 51,775 | 56,151 | 63,017 |
Actinium Pharmaceuticals, Inc. (ATNM)
Actinium Pharmaceuticals, Inc. (ATNM)